TX-MOGAS-INDUSTRIES
18.5.2023 05:34:29 CEST | Business Wire | Press release
MOGAS Industries, Inc. (MOGAS) will be celebrating its 50-year anniversary with a commemorative celebration on Thursday, May 18th, 2023. The company officially began at 8:20 p.m. on May 17th, 1973.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005845/en/
Matt Mogas (left) and Louis Mogas (right) pose next to a large MOGAS ball valve (Photo: Business Wire)
MOGAS has earned a global reputation as a leading severe service manufacturer for the most extreme industrial applications in power, mining, refining, petrochemical/chemical, oil & gas, and specialty application industries. Significant business units include Severe Service Valves, Systems & Consulting (modules), Surface Technologies (coatings), Service & Reliability.
Louis Mogas formed Mogas Machine Works in 1973 with 16 employees working under 19,000 sq ft of manufacturing space on a couple of acres. Today, privately owned MOGAS Industries employs over 325 people across six countries. Their Houston-based headquarters now has 100,000 sq ft of manufacturing capacity spanning 15 acres. Campus improvements, such as 'Class A' corporate offices, an advanced coating facility, a 3-acre wooded park and numerous facility upgrades attest to MOGAS' success—not only as a significant manufacturer—but also to the Company staying true to its original business philosophy of putting people before profits.
A significant part of MOGAS sales is international, with sales and service centers in China, Australia, Canada, South America, Africa, The Middle East, Europe and India. With representatives and technicians in more than 40 countries, MOGAS is known for partnering with its customers to meet the ever-increasing challenges of severe-service applications.
On the occasion of the company’s 50th anniversary, MOGAS CEO/COO Matt Mogas notes: “I feel incredibly blessed to have worked with so many great employees, representatives, and customers these last 33 years. They have made a meaningful impact on MOGAS Industries and me personally. I feel honored to stand on the shoulders of the great men that came before me at MOGAS, especially Sam Furman, Tommy Bright, Cary Lorenz and of course my father, Louis Mogas, the grand architect, master, creator of our culture, beliefs and vision.”
Serving the community is ingrained in the MOGAS culture. The Company contributes significant resources to many worthy causes and enthusiastically supports their employees’ robust spirit of volunteerism. Charitable contributions to organizations include: Ronald McDonald House, MS150, Camp for All, The Periwinkle Foundation, and business partnerships with local elementary and junior schools. The Company also supports private initiatives for public good, focusing on quality of life.
The entire MOGAS organization is proud of this momentous achievement.
For more information, please contact MOGAS Industries at 281.449.0291 or Email: marketing@mogas.com
About MOGAS Industries, Inc.
MOGAS Industries Inc. is the most trusted severe service technology company, providing world-renowned services and the best severe service, application-specific products for critical applications in power, mining, oil & gas, refining, chemical/petrochemical and specialty industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005845/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom